Trial Number
208-13
Condition
Lung Cancer
Participant Age Range
18 years and older
Participant Gender
Any
Enrolling Participants
Yes
Overview
“Therapeutically Targeting Non-Small Cell Lung Tumors with Loss of LKB1”
The future of lung cancer care will likely consist of personalized therapy in which treatments are matched to genetic alterations of each individual's particular cancer. The purpose of this study is to collect surgical samples obtained during removal of non-small cell lung cancers. A portion of the surgically removed lung cancer will be used to design a treatment for lung cancers that contain genetic changes (or alterations) in the LKB1 gene, a protein enzyme that is necessary to cell metabolism and the stability of energy. Drugs will be tested on these lung tumors removed during surgery with the hope that these medicines will constitute low toxicity (safe) personalized treatments for patients whose lung cancers have LKB1 alterations.